1Grunhage F, Fischer HP, Sauerbruch T, et al. Drug- and toxin-induced hepatotoxicity. Z Gastroenterol, 2003, 41 : 565-578.
2Zhou Y, Yang L, Liao Z, et al. Epidemiology of drugqnduced liver injury in China: a systematic analysis of the Chinese literature including 21, 789 patients. Eur J Gastroenterol Hepatol, 2013, 25: 825-829.
3Lin J, Moore D, Hockey B, et al. Drug-induced hepatotoxieity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. Liver Int, 2014, 34: 576-582.
4Ghabril M, Fontana R, Rockey D, et al. Drug-induced liver injury caused by intravenously administered medications the drug-induced liver injury network experience. J Clin Gastroenterol, 2013, 47:553 -558.
5Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44: 1581-1588.
6Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology, 2005, 42: 481-489.
8Papay JI, Clines D, Raft R, et ai. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol, 2009, 54: 84-90.
9Sebastiani G, Gkouvatsos K, Maffettone C, et al. Accelerated CC14-induced liver fibrosis in Hjv/ mice, associated with an oxidative burst and precocious profibrogenic gene expression. PLoS One, 2011, 6: e25138.
10Lopez-Diazguerrero NE, Luna-Lpez A, Gutiarrez-Ruiz MC, et al. Susceptibility of DNA to oxidative stressors in young and aging mice. Life Sci, 2005, 77: 2840-2854.
5Steele MA, Burk RF, Desprez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 1991,99 : 465-471.
6Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1" null" mutation J Gastroenterol Hepatol, 2001,16 : 1033-1037.
7Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis, 2008,12: 994-1002.
8Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol, 1990, 11 : 272-276.
9Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis, 2000, 4 : 256 -261.
10Lin HJ, Han CY, Bernsteiu DA, et al. Ethnic distribution of the glutathione transferase Mu 1-1 ( GSTM1 ) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis, 1994,15 : 1077-1081.
7Chen M, Bisgin H, Tong L, et al. Toward predictive models for drug induced liver injury in humans: are we there yet?[J]. Biomarkers Med,2014,8:201-213.
8Araathieu R, Levesque E, Merle JC, et al. Severe toxic acute liver failure: etiology and treatment[J]. Ann Fr Anesth Reanim,2013,32:416-421.
9Han D, Data L, Win S, et al. Regulation of drug-induced liver injury by signal transduction pathways: critical role of rnitochondria[J]. Trends Pharmacol Sci,2013,34:243-253.
10Daly AK. Drug-induced liver injury: past, present and future[J]. Pharm aeogenomies,2010,11:607-61 l.
